Provided by Tiger Fintech (Singapore) Pte. Ltd.

Gilead Sciences

117.41
+1.371.18%
Post-market: 117.00-0.4100-0.35%19:59 EST
Volume:14.41M
Turnover:1.69B
Market Cap:146.22B
PE:308.97
High:118.42
Open:115.65
Low:114.79
Close:116.04
Loading ...

Are Investors Undervaluing ANI Pharmaceuticals (ANIP) Right Now?

Zacks
·
17 Feb

Gilead Sciences, Inc. (GILD) Hit a 52 Week High, Can the Run Continue?

Zacks
·
17 Feb

Gilead Sciences, Inc. (GILD): A Bull Case Theory

Insider Monkey
·
17 Feb

Buy Recommendation for Gilead Sciences: Promising Outlook with Seladelpar Approval and Robust Drug Portfolio

TIPRANKS
·
17 Feb

Gilead Sciences (NASDAQ:GILD) Is Increasing Its Dividend To $0.79

Simply Wall St.
·
15 Feb

US Equity Indexes Rise in Week Amid Tariff Tumult, Hot Inflation, Fed on Pause

MT Newswires Live
·
15 Feb

Gilead Sciences Inc. Stock Underperforms Friday When Compared To Competitors

Dow Jones
·
15 Feb

Gilead Sciences Inc. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
14 Feb

Biotech Stock Roundup: GILD Up on Q4 Results, BIIB, BMY Down on 2025 Guidance

Zacks
·
14 Feb

Daiwa Securities Adjusts Price Target on Gilead Sciences to $104 From $90, Keeps Neutral Rating

MT Newswires Live
·
14 Feb

BUZZ-Ideaya Biosciences falls as quarterly loss widens

Reuters
·
13 Feb

IDEAYA Biosciences Launching Gilead Trial Collaboration to Evaluate Trodelvy, IDE397 Combination in Lung Cancer

MT Newswires Live
·
13 Feb

IDEAYA Biosciences Inc: IDEAYA Is Study Sponsor and Gilead Will Provide Supply of Trodelvy to IDEAYA

THOMSON REUTERS
·
13 Feb

IDEAYA Biosciences Inc: IDEAYA and Gilead Retain Commercial Rights to Their Respective Compounds

THOMSON REUTERS
·
13 Feb

IDEAYA Announces Further Gilead Sciences Clinical Study Collaboration Evaluating Combination of Trodelvy® and IDE397 in MTAP-Deletion NSCLC

PR Newswire
·
13 Feb

Gilead upgraded to Buy from Hold at DZ Bank

TIPRANKS
·
13 Feb